Mackay Shields Portfolio holdings
MacKay Shields is a fixed income manager, wholly owned through a holding company by New York Life Insurance Company. It started in 1938 as an economic consulting firm, registered as an investment adviser in 1969, and was bought by New York Life in 1984. Separate teams each run their own investment process, offering strategies through custom accounts, mutual funds, ETFs and private funds. Its clients are mainly institutions such as insurance companies, corporate pension funds, endowments and foundations.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$19.8M |
| 2 |
TSMC
TSM
|
+$10.7M |
| 3 |
Match Group
MTCH
|
+$6.4M |
| 4 |
Vistra
VST
|
+$5.66M |
| 5 |
NYLIM MacKay Core Plus Bond ETF
CPLB
|
+$4.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$36.4M |
| 2 |
Microsoft
MSFT
|
+$10.8M |
| 3 |
Apple
AAPL
|
+$10.4M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$6.41M |
| 5 |
Nuveen AMT-Free Quality Municipal Income Fund
NEA
|
+$6.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.64% |
| 2 | Technology | 13.48% |
| 3 | Financials | 7.41% |
| 4 | Healthcare | 6.8% |
| 5 | Consumer Discretionary | 6.29% |
Similar funds
Mackay Shields's Q3 2021 Portfolio in Review
As of Q3 2021, Mackay Shields held 722 positions worth $10.6B, down 0.27% from $10.6B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Mackay Shields withdrew a net $2.95B in Q3 2021, closing 11 positions and reducing 477 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $6.41M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Mackay Shields opened a new position in Moderna worth $20.7M.
- Mackay Shields's largest Q3 2021 buy was Moderna: 53,663 shares worth $20.7M.
- Mackay Shields added most to TSMC in Q3 2021, an estimated $10.7M increase.
- Mackay Shields's biggest Q3 2021 reduction was Lam Research, cutting an estimated $36.4M.
- Mackay Shields fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $6.41M.
- Mackay Shields's ten largest holdings make up 26% of its $10.6B portfolio in Q3 2021.
- Mackay Shields opened 10 new positions and closed 11 in Q3 2021.
- Mackay Shields's portfolio value fell 0.27% quarter-over-quarter to $10.6B.
Based on Mackay Shields's 13F filing for Q3 2021, filed 12 Nov 2021.